Liver Cirrhosis - Comprehensive Overview

Definition

• Sleisenger and Fordtran's Gastrointestinal and Liver Disease, p. 1163
• Robbins & Kumar Basic Pathology, p. 598

Gross and Histological Appearance

Gross specimen: Cirrhosis from chronic viral hepatitis. Note the broad scars separating bulging regenerative nodules over the liver surface.

Masson trichrome stain: (A) Thick bands of collagen (blue) with rounded cirrhotic nodules in an active drinker. (B) After 1 year of abstinence, most scars have regressed.

• Micronodular (<3 mm): typical of alcohol-related cirrhosis
• Macronodular (>3 mm): typical of post-viral cirrhosis
• Mixed pattern can occur with alcohol cessation

• Robbins & Kumar Basic Pathology, p. 598

Etiology

Common Causes

• Harrison's Principles of Internal Medicine 22E, p. (Table 355-1)

Pathogenesis

The Central Role of Hepatic Stellate Cells

• Upregulation of smooth muscle actin
• Increased motility and contractility
• Production of extracellular matrix (initially fibronectin, then collagen type 1)

• Platelet-derived growth factor (PDGF) - kinase pathway
• Transforming growth factor-beta (TGF-β)
• Integrin signaling pathways

• Portal fibroblasts - implicated in biliary/cholestatic forms of fibrosis (PBC, PSC)
• Macrophages (Kupffer cells) - release inflammatory cytokines that transactivate HSCs; some subsets promote fibrosis, others aid resolution
• Sinusoidal endothelial cells - paracrine role in stellate cell activation
• Epithelial cells - injury (apoptosis, sterile necrosis, inflammation) is the initiating step

• Sleisenger and Fordtran's Gastrointestinal and Liver Disease, p. 1164

Clinical Features

Compensated vs. Decompensated Cirrhosis

Symptoms and Signs

• Anorexia, weight loss, weakness, fatigue
• Jaundice (chronic severe jaundice → pruritus, sometimes severe)

• Ascites (85% of ascites is caused by portal hypertension from cirrhosis)
• Esophageal/gastric varices (~40% of advanced cases, risk of fatal hematemesis)
• Caput medusae (dilated periumbilical veins)
• Hemorrhoids
• Splenomegaly → hypersplenism (thrombocytopenia, pancytopenia)

• Hypoalbuminemia → edema
• Coagulopathy (prolonged PT/INR)
• Jaundice

• Palmar erythema
• Spider angiomas (on trunk and upper limbs)
• Gynecomastia
• Hypogonadism, testicular atrophy

Diagram: Systemic consequences of portal hypertension in cirrhosis - from hepatic encephalopathy to ascites, varices, splenomegaly, and reproductive effects.

• Robbins & Kumar Basic Pathology, p. 598-599

Complications

Portal Hypertension-Related

• Ascites - transudate (protein <3 g/dL), serum-to-ascites albumin gradient (SAAG) ≥1.1 g/dL
• Variceal hemorrhage - esophagogastric varices in ~40% of advanced liver disease; potentially fatal
• Hepatic hydrothorax
• Spontaneous bacterial peritonitis (SBP)

Hepatic Dysfunction

• Hepatic encephalopathy - portosystemic shunting of ammonia and other toxins
• Coagulopathy - impaired clotting factor synthesis
• Hepatorenal syndrome (HRS) - functional renal failure in decompensated cirrhosis

Cardiopulmonary

• Hepatopulmonary syndrome - intrapulmonary vascular dilation → hypoxemia
• Portopulmonary hypertension
• Cirrhotic cardiomyopathy

Metabolic and Endocrine

• Adrenal insufficiency
• Hypogonadism
• Malnutrition / sarcopenia
• Osteoporosis

Hematologic

• Thrombocytopenia (hypersplenism)
• Anemia
• Venous thrombosis (paradoxically increased due to impaired anticoagulant synthesis)

Oncologic

• Hepatocellular carcinoma (HCC) - most chronic liver diseases predispose; cirrhosis is the strongest risk factor for HCC worldwide
• Cholangiocarcinoma
• Sleisenger and Fordtran's Gastrointestinal and Liver Disease, pp. 1164-1167

Diagnosis

Laboratory Tests

• Liver enzymes: AST, ALT elevated (AST:ALT >2:1 in alcohol-related disease)
• Synthetic function: Low albumin, prolonged PT/INR
• Bilirubin: Elevated in decompensated disease
• CBC: Thrombocytopenia (platelet <160,000/mm³ supports diagnosis; ≥160,000 argues against)
• APRI score (AST/platelet ratio index): >2 suggests cirrhosis

Non-Invasive Fibrosis Assessment

• Serum-based scores: FIB-4, APRI, Bonacini score, Lok index
• Transient elastography (Fibroscan):

  • 14 kPa → suggests cirrhosis

  • 19.5 kPa → esophageal varices unlikely if below this

  • 21 kPa → portal hypertension with complications

• ARFI elastography: >2.6 m/sec → cirrhosis
• MR elastography (MRE): >5.9 kPa → cirrhosis (liver biopsy usually not needed to confirm)
• Increasing spleen stiffness on elastography is associated with portal hypertension onset

Imaging

• Ultrasound: Small nodular liver + splenomegaly + collaterals + ascites
• CT/MRI: Cross-sectional imaging for detailed assessment and HCC screening

Liver Biopsy

• Stage 3 = bridging fibrosis with nodularity
• Stage 4 = cirrhosis

• Sleisenger and Fordtran's Gastrointestinal and Liver Disease, pp. 1164-1167

Prognosis Scoring

Child-Pugh Score

• Class A (5-6 points): Well-compensated, 1-year survival ~100%
• Class B (7-9 points): Significant impairment
• Class C (10-15 points): Decompensated, 1-year survival ~45%

MELD Score (Model for End-Stage Liver Disease)

• MELD ≥15 → consider liver transplant listing
• Higher MELD = higher 90-day mortality
• Used for organ allocation priority by UNOS

• Compensated cirrhosis: 5x increased risk of death vs. general population
• Decompensated cirrhosis: 10x increased risk
• Chronic liver disease is the 12th leading disease cause of death in the USA; in ages 45-64, it is the 3rd leading cause of death
• In compensated stages, the most common cause of death is cardiovascular disease, not liver failure
• In decompensated cirrhosis, death is usually due to complications of portal hypertension, HCC, or sepsis
• Sleisenger and Fordtran's Gastrointestinal and Liver Disease, pp. 1167-1169

Management

General Measures

• Treat the underlying cause (most important):
  • Abstinence from alcohol
  • Antiviral therapy for HBV (tenofovir, entecavir) and HCV (direct-acting antivirals - >95% cure rate)
  • Ursodeoxycholic acid for PBC
  • Immunosuppression for autoimmune hepatitis
  • Phlebotomy/chelation for hemochromatosis
• Avoid hepatotoxins: NSAIDs, nephrotoxic agents, sedatives
• Vaccinate: Hepatitis A, Hepatitis B, pneumococcal, influenza
• Nutrition: High-calorie, protein-adequate diet (1.2-1.5 g/kg/day protein); treat sarcopenia

Management of Specific Complications

• Sodium restriction (<2 g/day)
• Diuretics: spironolactone (first-line) ± furosemide
• Large-volume paracentesis + albumin infusion for refractory ascites
• TIPS (transjugular intrahepatic portosystemic shunt) for refractory cases

• Primary prophylaxis: non-selective beta-blockers (propranolol, nadolol, carvedilol)
• Endoscopic variceal band ligation (EVL)
• Active bleed: octreotide/terlipressin + EVL ± TIPS

• Lactulose (reduces ammonia absorption)
• Rifaximin (non-absorbable antibiotic, reduces gut ammonia-producing bacteria)
• Identify and treat precipitants (infection, GI bleed, constipation, medications)

• Third-generation cephalosporins (cefotaxime)
• Long-term norfloxacin prophylaxis in high-risk patients

• Discontinue diuretics, nephrotoxins
• IV albumin + vasoconstrictors (terlipressin or norepinephrine + albumin)
• TIPS as bridge to transplantation

• Ultrasound ± AFP every 6 months in all cirrhotic patients

Reversal of Fibrosis

• Hepatitis C: fibrosis regression after sustained virologic response (SVR)
• Alcohol: significant regression after prolonged abstinence
• Autoimmune hepatitis: regression with immunosuppression

Liver Transplantation

• Definitive treatment for end-stage cirrhosis
• Indications: MELD ≥15, decompensated cirrhosis refractory to treatment, HCC within Milan criteria
• 5-year survival post-transplant: ~70-80%
• Patients with ACLF listed for transplant have high risk of delisting or death (~50% within 6 months if not transplanted)

Acute-on-Chronic Liver Failure (ACLF)

• Definition: Chronic liver disease ± cirrhosis + acute decompensation + hepatic and extrahepatic organ failure + high short-term mortality (within 3 months without specific treatment)
• Precipitants (West): Bacterial infection (most common), alcohol-associated hepatitis
• Precipitants (East): HBV reactivation, HEV superinfection, alcohol
• Pathophysiology: Gut microbiome dysbiosis → bacterial translocation → systemic inflammation → multiorgan failure
• Mortality: ~50% in-hospital; higher than acute liver failure after 1 week

• Type A: Underlying chronic liver disease without cirrhosis
• Type B: Underlying compensated cirrhosis
• Type C: Underlying decompensated cirrhosis
• Sleisenger and Fordtran's Gastrointestinal and Liver Disease, pp. 1170-1171

Summary Table

• Sleisenger and Fordtran's Gastrointestinal and Liver Disease (Chapter 74)
• Robbins & Kumar Basic Pathology (Chapter 14)
• Harrison's Principles of Internal Medicine, 22nd Ed. (Chapter 355)

Recent evidence note: A 2025 systematic review (PMID 40588713) addresses the hepatic fibrosis-to-HCC axis with emerging therapeutic targets. Research in sarcopenia and MASLD-related cirrhosis is also active (PMID 39214253). No major shifts in core cirrhosis management guidelines have been identified in recent meta-analyses.

Classification of Liver Cirrhosis

1. Morphological Classification (WHO, 1977)

Top: Gross cirrhotic liver. Bottom: Regenerative nodules separated by bridging fibrosis (H&E stain).

Important caveat: The WHO morphological classification has low specificity - the same pattern can result from different diseases, and a single disease can show several patterns. Nodule size changes over time (dynamic process). This system is therefore considered to have little utility in defining etiology and has largely been replaced by etiological classification.

• Schwartz's Principles of Surgery, 11th Ed., p. 1390
• Mulholland and Greenfield's Surgery, 7th Ed., p. 2858

2. Etiological Classification

A. Alcohol-Related

• Most common cause in Western countries (accounts for ~30% of liver transplants in USA)
• Classically produces micronodular cirrhosis
• Minimum threshold: >30 g/day (women), >50 g/day (men) for ≥5 years
• Histology: steatosis → alcoholic steatohepatitis → fibrosis → cirrhosis; Mallory-Denk bodies; megamitochondria

B. Viral Hepatitis

• Chronic Hepatitis B - can cause cirrhosis with or without prior hepatitis
• Chronic Hepatitis C - one of the leading causes worldwide; SVR with direct-acting antivirals can halt and reverse fibrosis
• Hepatitis D - superinfection on HBV accelerates cirrhosis
• Typically produces macronodular pattern

C. Metabolic / Steatotic Liver Disease

• MASLD/MASH (formerly NAFLD/NASH) - now the most common chronic liver disease worldwide; ~1 in 10 NASH patients progress to cirrhosis
• Hemochromatosis - iron overload → hepatocyte injury
• Wilson's disease - copper accumulation
• Alpha-1 antitrypsin deficiency - misfolded protein accumulation in hepatocytes
• Cystic fibrosis - biliary involvement
• Glycogen storage diseases (types IA, III, IV), Tyrosinemia, Galactosemia

D. Biliary / Cholestatic

• Primary Biliary Cholangitis (PBC) - autoimmune destruction of small intrahepatic bile ducts; antimitochondrial antibodies in 95%; progresses from non-suppurative cholangitis → bridging fibrosis → cirrhosis
• Primary Sclerosing Cholangitis (PSC) - inflammation and fibrosis of intra- and extrahepatic ducts; associated with IBD
• Autoimmune cholangiopathy
• Biliary obstruction (secondary biliary cirrhosis)

E. Autoimmune

• Autoimmune hepatitis - responds to immunosuppression; cirrhosis may regress with treatment

F. Vascular / Cardiac

• Cardiac cirrhosis - chronic right heart failure → centrilobular congestion → "nutmeg liver" → fibrosis
• Budd-Chiari syndrome - hepatic vein outflow obstruction

G. Drugs and Toxins

• High-dose vitamin A (chronic)
• Methotrexate (cumulative dose)
• Amiodarone, isoniazid, and others

H. Cryptogenic

• No identifiable cause after full workup; may represent unrecognized MASLD or burnt-out autoimmune hepatitis
• Schwartz's Principles of Surgery, p. 1390 (Table 31-3)
• Harrison's Principles of Internal Medicine, 22nd Ed.

3. Clinical / Functional Classification

Compensated vs. Decompensated

Four-Stage Model (Baveno / D'Amico Staging)

Portal Hypertension Sub-staging (Current Guidelines)

• Mulholland and Greenfield's Surgery, 7th Ed., p. 2894

4. Prognostic Scoring Classification

A. Child-Pugh Score

• Class B (score ≥7) = accepted minimum for liver transplant listing (historical criterion)
• Limitations: subjective parameters (ascites, encephalopathy grading), ceiling effect, less center-to-center consistency

B. MELD Score (Model for End-Stage Liver Disease)

• All objective variables
• Wider scoring range
• Better predicts short-term survival
• Superior for predicting post-TIPS outcomes
• Harrison's Principles of Internal Medicine, 22nd Ed., p. (Table 347-6)
• Tietz Textbook of Laboratory Medicine, 7th Ed., p. (Table 51.9)

Summary Diagram

LIVER CIRRHOSIS CLASSIFICATION
│
├── 1. MORPHOLOGICAL (WHO 1977 - limited utility)
│       ├── Micronodular (<3mm) → Alcohol, hemochromatosis
│       ├── Macronodular (>3mm) → Viral hepatitis, autoimmune
│       └── Mixed → Transitional state
│
├── 2. ETIOLOGICAL (most clinically useful)
│       ├── Alcohol-related
│       ├── Viral (HBV, HCV, HDV)
│       ├── Metabolic (MASLD, hemochromatosis, Wilson's, A1AT)
│       ├── Biliary (PBC, PSC)
│       ├── Autoimmune hepatitis
│       ├── Vascular (cardiac, Budd-Chiari)
│       ├── Drug/toxin-induced
│       └── Cryptogenic
│
├── 3. CLINICAL (prognostic staging)
│       ├── Compensated (Stage 1-2)
│       │     ├── Without CSPH (HVPG <10)
│       │     └── With CSPH (HVPG ≥10)
│       └── Decompensated (Stage 3-4)
│             ├── Ascites
│             ├── Variceal hemorrhage
│             └── Encephalopathy
│
└── 4. PROGNOSTIC SCORES
        ├── Child-Pugh (Class A/B/C) → surgical risk, historical transplant criterion
        ├── MELD (0-40+) → transplant listing, short-term mortality
        ├── MELD-Na → adds sodium for accuracy
        └── PELD → pediatric patients (<12 yrs)